title: Surfactant metabolism and anti-oxidative capacity in hyperoxic neonatal rat lungs: effects of keratinocyte growth factor on gene expression in vivo.
abstract: Development of preterm infant lungs is frequently impaired resulting in bronchopulmoary dysplasia (BPD). BPD results from interruption of physiologic anabolic intrauterine conditions, the inflammatory basis and therapeutic consequences of premature delivery, including increased oxygen supply for air breathing. The latter requires surfactant, produced by alveolar type II (AT II) cells to lower surface tension at the pulmonary air:liquid interface. Its main components are specific phosphatidylcholine (PC) species including dipalmitoyl-PC, anionic phospholipids and surfactant proteins. Local antioxidative enzymes are essential to cope with the pro-inflammatory side effects of normal alveolar oxygen pressures. However, respiratory insufficiency frequently requires increased oxygen supply. To cope with the injurious effects of hyperoxia to epithelia, recombinant human keratinocyte growth factor (rhKGF) was proposed as a surfactant stimulating, non-catabolic and epithelial-protective therapeutic. The aim of the present study was to examine the qualification of rhKGF to improve expression parameters of lung maturity in newborn rats under hyperoxic conditions (85% O(2) for 7 days). In response to rhKGF proliferating cell nuclear antigen mRNA, as a feature of stimulated proliferation, was elevated. Similarly, the expressions of ATP-binding cassette protein A3 gene, a differentiation marker of AT II cells and of peroxiredoxin 6, thioredoxin and thioredoxin reductase, three genes involved in oxygen radical protection were increased. Furthermore, mRNA levels of acyl-coA:lysophosphatidylcholine acyltransferase 1, catalyzing dipalmitoyl-PC synthesis by acyl remodeling, and adipose triglyceride lipase, considered as responsible for fatty acid supply for surfactant PC synthesis, were elevated. These results, together with a considerable body of other confirmative evidence, suggest that rhKGF should be developed into a therapeutic option to treat preterm infants at risk for impaired lung development.
authors.affiliation: Institute of Physiological Chemistry, Medical Faculty Carl Gustav Carus, University of Technology Dresden, Fiedlerstr 42, 01307 Dresden, Germany. koslowsk@rcs.urz.tu-dresden.de
authors.forename: Roland
authors.initials: R
authors.lastname: Koslowski
authors.forename: Michael
authors.initials: M
authors.lastname: Kasper
authors.forename: Katharina
authors.initials: K
authors.lastname: Schaal
authors.forename: Lilla
authors.initials: L
authors.lastname: Knels
authors.forename: Marco
authors.initials: M
authors.lastname: Lange
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Bernhard
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000975:Antioxidants / Q000378:metabolism*; D051523:Fibroblast Growth Factor 7 / Q000494:pharmacology*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D018496:Hyperoxia / Q000378:metabolism*; D008168:Lung / Q000187:drug effects* / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013501:Surface-Active Agents / Q000378:metabolism*
chemical_list: D000975:Antioxidants; C496453:FGF7 protein, human; D012333:RNA, Messenger; D013501:Surface-Active Agents; D051523:Fibroblast Growth Factor 7